AI-Driven Asthma & Allergy Co-Pilot: A Strategic Analysis and Product Blueprint

I. Executive Summary: The AI Co-Pilot Opportunity in Proactive Respiratory Care

The digital health market for chronic respiratory diseases, particularly asthma and allergies, is defined by a significant market failure. Current solutions are fragmented and fundamentally reactive, functioning either as digital diaries requiring burdensome manual data entry [1] or as hardware-tethered adherence monitors focused narrowly on medication use.[3] This leaves a critical gap between the profound patient need for proactive, predictive guidance and the limited capabilities of existing tools. The recent, complete discontinuation of Teva Pharmaceutical's Digihaler product line serves as a stark market signal, underscoring the inherent weaknesses and commercial unsustainability of a purely hardware-centric, pharmaceutical-led business model.[5] This withdrawal highlights an urgent need for a more integrated, software-driven, and patient-centric paradigm.

Simultaneously, a confluence of mature technologies has created a unique inflection point for innovation. Peer-reviewed clinical research has now established that artificial intelligence (AI) models can diagnose and differentiate respiratory conditions via acoustic analysis of cough and wheeze sounds with exceptionally high accuracy, achieving an area under the curve (AUC) greater than 0.95.[6] This transforms the common smartphone into a powerful, non-invasive diagnostic sensor. Concurrently, the ubiquity of consumer wearables and the availability of rich, real-time environmental data streams (e.g., pollen counts, Air Quality Index) enable the passive collection of a new class of "digital biomarkers".[7] This convergence allows for a fundamental shift in disease management—from a model based on manual, subjective, and often inaccurate patient recall to one based on passive, continuous, objective, and predictive monitoring.

This report puts forth the strategic recommendation for the development of an **AI-Driven Asthma & Allergy Co-Pilot**. This platform will be a regulated Software as a Medical Device (SaMD) that functions as a proactive disease management partner for patients. Its core, defensible differentiator will be the fusion of three key technologies: **passive acoustic**

monitoring for objective, real-time symptom detection; **predictive analytics** for forecasting exacerbation risk; and **personalized environmental intelligence** for precise trigger identification and avoidance. This creates a powerful "sense, predict, and advise" feedback loop that directly addresses the core patient Job to be Done: "Help me feel in control and avoid my next attack."

The initial Minimum Viable Product (MVP) will focus on a mobile application that leverages the smartphone's microphone for on-device AI analysis of nocturnal cough and wheeze events. It will correlate these objective acoustic biomarkers with user-logged symptoms and localized environmental data. This focused MVP provides immediate, high-value insight with minimal user burden, establishes a proprietary data collection flywheel, and charts a clear, de-risked path toward regulatory clearance as a novel respiratory monitoring tool.

II. The Patient Imperative: Deconstructing the Jobs to be Done (JTBD) for Asthma & Allergy Sufferers

To design a truly valuable solution, it is essential to move beyond a superficial list of symptoms and understand the deep, often unstated, needs of patients. The Jobs to be Done framework reveals the functional, social, and emotional "jobs" that individuals with asthma and allergies would "hire" a product to perform, providing a clear blueprint for value creation.

The Core Job: "Help me regain control over my life from an unpredictable disease."

At its heart, living with asthma or severe allergies is an exercise in managing uncertainty. Patients exist in a state of persistent, low-grade anxiety, acutely aware that their own bodies can betray them without warning.[9] The core symptoms—shortness of breath, chest tightness, wheezing, and coughing—are not merely physical discomforts; they are profound sources of fear, disruption, and a loss of autonomy.[11] This unpredictability forces a significant cognitive and emotional burden onto the patient, requiring constant vigilance, symptom tracking, and complex decision-making about medication and daily activities.[9] The result is a life constrained by the disease, marked by compromises that range from avoiding physical activity and social events to enduring disrupted sleep and reduced productivity at work.[9] The ultimate job a patient needs done is the restoration of control and predictability in their daily

lives.

Functional Job 1: "Help me understand what triggers my symptoms so I can avoid them."

Patients are acutely aware that their symptoms are caused by triggers, but they struggle to identify these factors with precision and confidence. The list of potential culprits is vast and highly individualized, encompassing environmental allergens like pollen, dust mites, and pet dander; airborne irritants such as smoke and chemical fumes; weather conditions like cold air and high humidity; and even internal states like stress.[10] The current best-practice solution for this job is a manual symptom and activity diary, a burdensome and often inconsistent process that relies heavily on patient diligence and memory.[9] This method frequently fails to capture the subtle, multifactorial correlations that define a person's unique trigger profile. Patients need an intelligent system that can automatically and passively connect the dots between their environment, their activities, and their physiological response, transforming a vague sense of "something set it off" into actionable, personalized intelligence.

Functional Job 2: "Tell me if my condition is getting worse *before* it becomes an emergency."

A primary source of patient anxiety is the potential for a gradual worsening of symptoms to escalate into a full-blown, life-threatening exacerbation or asthma attack.[9] Established warning signs of deteriorating control include an increased need for quick-relief (rescue) inhalers, more frequent awakenings at night due to symptoms, and a measurable decline in lung function via a peak flow meter.[9] However, recognizing and acting on these trends requires consistent monitoring and objective assessment, which can be challenging for patients. The job is to create an early warning system that shifts the management paradigm from reacting to a crisis to proactively intervening during a downward trend. Patients want to be alerted to subtle changes in their condition, enabling them to adjust their treatment in consultation with their physician and prevent a severe event.

Functional Job 3: "Help me use my medication correctly and effectively."

A critical but often overlooked failure point in asthma management is medication delivery. An astonishingly high percentage of patients—nearly 90% in some studies—demonstrate at least two critical errors in their inhaler technique.[16] These subtle errors, such as a half-second delay between actuation and inhalation, can substantially reduce the amount of medication deposited in the lungs, severely compromising treatment efficacy.[16] This is an "invisible" problem; patients are often completely unaware of their incorrect technique. Furthermore, adherence to long-term controller medications, which are essential for managing underlying inflammation, is a significant challenge, particularly among young adults navigating the transition to independent self-management.[18] The job to be done is not merely about sending medication reminders; it is about providing feedback and building confidence that the medication is being taken

and that it is being administered in a way that ensures its effectiveness.

Emotional & Social Job: "Help me feel 'normal' and reduce the mental burden of my condition."

The chronic nature of asthma and allergies exacts a heavy psychological toll. The constant effort required to breathe during flare-ups, coupled with disrupted sleep, leads to profound fatigue and a general feeling of low energy.[11] This physical exhaustion is compounded by the mental burden of the disease, which is linked to higher rates of anxiety and depression.[11] The cognitive load of perpetual self-monitoring is draining. For children and adolescents, this burden is magnified by social pressures. The need to carry and use inhalers, or to sit out of physical activities, can lead to feelings of embarrassment, exclusion, and isolation from peers.[11] The emotional job is to alleviate this mental weight. A successful solution must automate as much of the monitoring burden as possible, transforming the management tool from a demanding taskmaster into a silent, reassuring guardian that works in the background, restoring a sense of normalcy and freedom.

A crucial realization emerges from deconstructing these patient needs. Clinicians and existing digital tools ask patients to track key indicators of worsening control, such as nocturnal coughing and wheezing.[11] However, these critical symptoms are often not consciously registered by the sleeping patient or are subject to significant recall bias upon waking. This creates a fundamental gap in the data. The most objective, high-frequency data needed for accurate exacerbation prediction is largely invisible to both the patient and their care team. Groundbreaking research now demonstrates that AI algorithms can passively and accurately detect these acoustic biomarkers using only a smartphone microphone.[6] A tool that can

capture and analyze this "invisible data" would fill a massive evidence gap. It would unlock true predictive power by replacing subjective, intermittent recall with objective, continuous measurement, fundamentally altering the disease management paradigm.

III. The Digital Health Ecosystem: A Competitive Analysis

The current digital health landscape for asthma and allergies is comprised of three distinct and largely disconnected categories of competitors. No single incumbent player successfully integrates the key technological capabilities and user-centric design required to fulfill the patient's core job of proactive, predictive disease management. This fragmentation reveals a significant strategic opportunity.

Category 1: Smart Inhalers & Adherence Platforms (Hardware-First)

This category is defined by products that physically attach to or are integrated within a medication inhaler.

- **Key Players:** Propeller Health (acquired by ResMed) and Teva's Digihaler line (now discontinued).
- **Core Technology:** These platforms utilize add-on sensors (Propeller) or fully integrated electronics (Teva) to track medication actuation events, capturing the time, date, and sometimes the location of use.[3] More advanced versions, like the Digihaler, also measured inspiratory flow to provide a proxy for inhalation technique.[24] This data is transmitted via Bluetooth to a companion mobile application.
- **Value Proposition:** The primary value proposition is centered on improving medication adherence.[3] For patients, this means reminders and tracking. For clinicians and pharmaceutical partners, it provides objective data on medication usage patterns, which can inform treatment discussions and population health initiatives.[25]
- **Weaknesses:** This model is encumbered by significant weaknesses that have limited its market penetration and long-term viability. The reliance on physical hardware introduces high costs, complex supply chains, and logistical hurdles for both patients and providers. The business model is predominantly B2B, relying on partnerships with pharmaceutical companies, payers, or health systems, which creates barriers to direct patient access. Most critically, these devices track *adherence* to a therapeutic action but do not directly measure objective *symptoms* or clinical *outcomes*. The market-shaking decision by Teva

to discontinue its entire Digihaler portfolio in 2024 is a powerful testament to the failure of this hardware-centric strategy, likely stemming from challenges in securing reimbursement and demonstrating a compelling return on investment beyond simple adherence metrics.[5]

Category 2: Symptom & Trigger Tracking Apps (Software-Only, Manual Input)

This category includes a wide array of mobile applications that function as digital diaries.

- **Key Players:** AsthmaMD, myAsthma, Asthma Buddy, and general-purpose health trackers like Bearable.
- **Core Technology:** These are software-only applications that rely on manual user input to log symptoms (e.g., coughing, wheezing), peak flow measurements, medication use, and perceived triggers.[1] Some apps augment this manual data with external feeds for local pollen counts and Air Quality Index (AQI).[28]
- **Value Proposition:** Their goal is to empower patients with tools for self-management. They help users create digital asthma action plans, visualize their health trends over time, and facilitate the sharing of a consolidated health record with their clinicians.[26]
- **Weaknesses:** The foundational weakness of this category is its complete reliance on high user effort. This leads to significant "data fatigue," resulting in poor long-term engagement, inconsistent logging, and incomplete datasets.[29] The data that is collected is inherently subjective and susceptible to recall bias, limiting its clinical reliability. Furthermore, the market is saturated with apps of varying quality; many suffer from poor usability, are not based on current clinical guidelines (e.g., GINA), or are not localized for specific national healthcare systems, making their action plans and medication lists irrelevant for many users.[26]

Category 3: Environmental Data & Allergy Forecast Apps (Data-First)

This category focuses on providing external, environmental information to the user.

- **Key Players:** Zyrtec AllergyCast, Pollen.com's Allergy Plus, AirCare.
- **Core Technology:** These applications primarily leverage a smartphone's location services to pull in and display localized forecasts for environmental factors known to trigger allergies and asthma, such as pollen concentrations, AQI, and specific weather conditions.[33] More advanced apps, notably Zyrtec AllergyCast, employ basic machine

learning to correlate user-logged symptoms with this environmental data to generate a "personalized" symptom forecast.[36]

- **Value Proposition:** The core function is to help users proactively plan their activities and take measures to avoid exposure to known environmental triggers.
- **Weaknesses:** These tools are fundamentally one-dimensional. They provide information about the external world but lack any mechanism to measure the user's actual, objective physiological response. The "personalization" they offer is entirely dependent on the quality and consistency of manual symptom logging, inheriting all the weaknesses of the second category. They can report that ragweed pollen is high, but they cannot confirm if ragweed is a true trigger for a specific user or measure the resulting symptom burden objectively.

Analyzing these distinct competitive categories reveals a clear and compelling strategic opportunity. The hardware-first players capture objective *adherence* data but miss symptoms. The manual software players capture subjective *symptom* data but suffer from high user burden. The data-first players capture objective *environmental* data but lack any link to the patient's actual health status. Academic research has validated a fourth, crucial capability: the ability to capture objective *symptom* data (acoustic biomarkers) through software alone, using the smartphone's existing microphone.[6]

This creates an unoccupied strategic position for a solution that unifies these disparate data streams into a single, cohesive platform. A software-only product that combines **passively collected, objective symptom data (via AI-driven acoustics)** with **objective environmental data** and **patient-reported outcomes** can construct a uniquely comprehensive and clinically powerful picture of a patient's condition. This approach strategically avoids the fatal flaws of the hardware-centric model (cost, logistics, failed business model) while simultaneously overcoming the core weakness of existing software solutions (high user burden, subjective data). This fusion of capabilities represents the defensible "white space" in the market and forms the foundation of the AI Co-Pilot's competitive moat.

Competitive Matrix

Feature/ Company	**Propeller Health**	**Teva Digihaler (Discontinued)**	**Asthma MD**	**myAsthma**	**Zyrtec AllergyCast**	**AI Co-Pilot (Proposed)**

Core Technology	Add-on Bluetooth sensor for existing inhalers [3]	Integrated sensor in a proprietary inhaler [4]	Manual logging mobile app [26]	Manual logging mobile app with clinician portal [28]	Environmental data aggregation with manual symptom logging and basic ML correlation [36]	**On-device AI for passive acoustic biomarker monitoring, integrated with environmental data feeds and predictive analytics** [6]
Key Features	Adherence tracking, medication reminders, location-based trigger insights, clinician dashboard [3]	Adherence tracking, inspiratory flow measurement, companion app [24]	Symptom/peak flow diary, medication log, asthma action plan, data sharing [26]	Symptom/peak flow diary, action plan, inhaler technique videos, education modules, clinician dashboard [28]	Personalized pollen/allergy forecast, symptom tracker, interactive maps, weather data [45]	**Passive nocturnal cough/wheeze detection, exacerbation risk forecasting, personalized trigger-correlation insights, dynamic action plan, objectiv**

						e sympto m dashboa rd [6]
Business Model	B2B2C (Payers, Health Systems, Pharma) [25]	B2B (Pharma-led, prescripti on-tied) [48]	Free app, data for research, partnersh ip with device sales (peak flow meter) [39]	B2B (Commis sioned by NHS trusts and healthcar e providers) [40]	B2C (Freemiu m, brand marketin g for Zyrtec) [36]	**B2C Freemiu m (core features) with a Premium subscrip tion (advanc ed analytic s, reports) and a B2B2C channel for payers/p roviders (clinicia n dashboa rd, populati on health)**
Regulato ry Status	FDA-clea red Class II Medical Device [3]	FDA-appr oved as a drug-dev ice combinat ion product [4]	Wellness App (not a regulated medical device) [39]	NHS Apps Library listed, CE marked [40]	Wellness App (not a regulated medical device) [41]	**Phased: Wellness App (MVP) -> FDA-cle ared Class II SaMD (with**

						predictive features [53]
Differentiator	Objective adherence data from a hardware sensor.	Integrated hardware measuring adherence and inspiratory flow.	Early mover in digital asthma diaries with an option to contribute data to research.	Strong integration with UK's NHS clinical workflows and educational content.	Brand recognition and a simple, user-friendly interface for environmental forecasts.	**Passive, objective symptom detection via software alone, creating a proprietary data flywheel for superior predictive accuracy.**
Key Weakness	High cost and friction of hardware; does not track objective symptoms. [25]	Unsustainable business model, high cost, hardware dependency, market withdrawal. [5]	High user burden, subjective data, poor user ratings, outdated interface, not clinically validated. [31]	High user burden, subjective data, primarily UK-focused. [55]	One-dimensional (environmental data only); personalization is limited by inconsistent manual logging. [45]	**Requires building user trust for passive audio collection; needs to generate a large, proprietary dataset to realize**

						full predictive potential.

IV. AI-Powered Innovation Frontiers in Respiratory Health

The strategic foundation of the AI Co-Pilot rests on the integration of three distinct but synergistic frontiers of AI innovation. These technologies, validated in academic and clinical research, provide the technical capabilities to move beyond the limitations of the current market and deliver a truly proactive respiratory management solution.

1. Acoustic Biomarkers: The Objective Symptom Detector

The ability to objectively quantify respiratory symptoms using sound is the most significant technological leap enabling the Co-Pilot.

- **The Science:** Researchers have successfully applied AI, particularly lightweight deep learning models such as Convolutional Neural Networks (CNNs), Random Forests (RF), and Support Vector Machines (SVMs), to analyze audio signals of coughs and other respiratory sounds.[6] The core process involves capturing an audio signal (e.g., via a smartphone microphone), performing a time-frequency transformation using techniques like the Short-Time Fourier Transform (STFT) to create a spectrogram (a visual representation of the sound's frequency spectrum over time), and then feeding this image-like data into a classifier model trained to distinguish between different sound events.[6] This method effectively turns an auditory problem into an image recognition task, leveraging the power of modern computer vision algorithms.
- **Performance Validation:** The performance of these acoustic models is robust and has been validated in multiple studies. An ensemble model integrating several classifiers achieved an accuracy of 94.05% in differentiating between asthmatic and normal respiratory sounds.[6] Other studies have reported high sensitivity (the ability to correctly identify patients with the condition) of up to 89% and specificity (the ability to correctly identify healthy individuals) of up to 90%, with AUC values—a comprehensive measure of

diagnostic accuracy—exceeding 0.95.[6] Broader systematic reviews corroborate these findings, concluding that digital audio biomarkers consistently achieve high accuracies (in the 80–100% range) for asthma diagnosis.[38]

- **Strategic Significance:** This technology is transformative because it enables the passive, objective, and longitudinal quantification of key respiratory symptoms using a sensor that is already in the pocket of nearly every patient: the smartphone microphone. This directly addresses the "invisible data" gap, allowing for the capture of critical clinical indicators, such as the frequency of nocturnal coughing, which is a primary marker of worsening asthma control but is notoriously difficult for patients to self-report accurately.[11] By deploying this technology for ambient nocturnal monitoring, the Co-Pilot can gather high-fidelity data on disease activity without requiring any active user engagement, thereby overcoming the primary failure point of all manual tracking apps.

2. Predictive Analytics: The Exacerbation Early Warning System

Once objective symptom data can be captured, the next frontier is using it to forecast future risk.

- **The Science:** Machine learning models are uniquely suited to identifying complex, non-linear patterns in longitudinal health data to predict the likelihood of a future adverse event, such as an asthma exacerbation. A range of algorithms, from traditional logistic regression to more sophisticated methods like Gradient Boosting Machines (e.g., XGBoost, LightGBM) and Recurrent Neural Networks (e.g., LSTMs), have been successfully applied to this problem.[42]
- **Input Data:** The power of these models lies in their ability to synthesize diverse data streams. Successful models have been built using combinations of electronic health record (EHR) data, patient-reported symptoms, medication usage logs (with a particular focus on the frequency of rescue inhaler use), and emerging digital biomarkers such as heart rate variability from wearables.[8]
- **Performance Validation:** These predictive models have demonstrated moderate to good performance in clinical studies. A notable study from the Cleveland Clinic, using a LightGBM model trained on EHR data, achieved an impressive AUC of 0.88 for predicting asthma-related emergency department (ED) visits and 0.85 for predicting hospitalizations.[42] While meta-analyses show a wider range of performance, with pooled AUCs typically between 0.67 and 0.76 for predicting ED visits, this still represents a clinically meaningful level of predictive accuracy that can be used for patient stratification and early intervention.[59]
- **Strategic Significance:** The AI Co-Pilot is positioned to significantly advance the state-of-the-art in this domain. By introducing passively collected acoustic biomarker data as a novel, high-frequency input feature, the platform's predictive models can

potentially achieve a new level of accuracy. Existing models are limited by the intermittent and often subjective nature of their inputs (e.g., annual clinical data, biased patient recall). The Co-Pilot's ability to feed a continuous stream of objective symptom data into its models will enable the creation of a dynamic, personalized risk score (e.g., "Your risk of a flare-up in the next 7 days is elevated from 15% to 45%"). This transforms the patient experience from reactive fear to proactive, data-informed action.

3. Personalized Exposomics: The Intelligent Trigger Finder

The final AI frontier involves moving from generic environmental alerts to truly personalized trigger identification.

- **The Science:** Leading allergy and immunology research organizations, such as the European Academy of Allergy and Clinical Immunology (EAACI), are actively promoting the use of AI and ML to build sophisticated causality models that link an individual's complex environmental exposures (their "exposome") to the onset of allergic disease and asthma symptoms.[47] This advanced field, known as exposomics, involves the large-scale analysis of environmental data streams and their correlation with individual health outcomes.
- **Input Data:** This capability is fueled by combining a patient's geolocation data with real-time, high-resolution data feeds for air quality (e.g., PM2.5, ozone), specific pollen types (e.g., ragweed, birch), and meteorological conditions (e.g., humidity, temperature), and then mapping this to the patient's symptom data.[34]
- **Strategic Significance:** This technology allows the AI Co-Pilot to transcend the generic and often unhelpful alerts of current allergy apps (e.g., "Pollen is high today"). By precisely correlating an individual's objective, time-stamped acoustic symptom data (e.g., "Your nocturnal cough frequency increased by 50% at 3 AM last night") with granular, time-stamped environmental data (e.g., "This coincided with a spike in local ragweed pollen and a 10-degree drop in temperature"), the system can learn a user's unique trigger profile with high confidence. This enables highly personalized and actionable advice (e.g., "Ragweed, one of your likely triggers, is forecasted to peak tomorrow between 6 AM and 10 AM. Consider taking your controller medication tonight and limiting outdoor activity during those hours"). This transforms the product from a simple data repository into an intelligent, personalized advisory service.

V. Blueprint for the AI Co-Pilot: Product Strategy and MVP Definition

Translating the strategic analysis into an executable product plan requires a disciplined approach to feature prioritization and a sharply focused Minimum Viable Product (MVP). This section outlines the comprehensive feature backlog and defines a differentiated MVP designed for rapid value delivery and strategic data acquisition.

Prioritization Framework

A hybrid prioritization model will be employed to ensure a balanced and strategic approach to feature development, aligning user needs with business objectives and technical feasibility.

- **MoSCoW (Must Have, Should Have, Could Have, Won't Have):** This framework will be used to define the non-negotiable core feature set for the MVP ("Must Haves") and to sequence subsequent development phases. It provides clear boundaries for the initial product launch.
- **RICE (Reach, Impact, Confidence, Effort):** Within each MoSCoW category, the RICE scoring model will be used to quantitatively rank features. This framework forces a rigorous evaluation of how many users a feature will affect (Reach), how much it will impact their core needs (Impact), the level of confidence in the estimates (Confidence), and the engineering resources required (Effort). This ensures that development time is allocated to the highest-value activities.
- **Kano Model (Basic, Performance, Delighter):** This model will be used to analyze the user-value proposition of each feature. The goal is to ensure the product backlog includes features that meet fundamental expectations ("Basic" attributes), provide scalable value as they are improved ("Performance" attributes), and create a unique, differentiated, and delightful user experience ("Delighter" attributes). The MVP's success hinges on delivering a core "Delighter" to drive initial adoption and engagement.

Prioritized Feature Backlog

The following table represents a prioritized backlog for the AI Co-Pilot, illustrating how the hybrid framework is applied to create a strategic product roadmap.

Feature	Feature	User Story	MoSCo	RICE Score	Kano Categor	Technic al	Support ing

ID	Name	(JTBD Alignment)	W	(Illustrative)	y	Components	Evidence
F01	**Passive Nocturnal Acoustic Monitoring**	As a patient, I want the app to automatically track my coughing and wheezing while I sleep, so that I can understand my nighttime symptoms without any effort.	**Must Have**	R:10 I:10 C:9 E:4 = **22.5**	**Delighter**	On-device AI/ML model (CNN), background audio processing, secure local data storage.	[6]
F02	**Daily Check-in & Symptom Logger**	As a patient, I want a quick and easy way to log my key sympto	**Must Have**	R:10 I:8 C:10 E:2 = **40**	**Basic**	UI/UX for quick data entry, FHIR-compliant data model for	[11]

		ms and rescue inhaler use, so I can connect how I feel to my objective data.				symptoms and medications.	
F03	**Personalized Environmental Dashboard**	As a patient, I want to see the specific pollen and air quality levels in my exact location, so I can understand my environmental exposure.	**Must Have**	R:10 I:7 C:10 E:2 = **35**	**Performance**	API integrations with pollen/AQI/weather data providers, location services.	34
F04	**Correlational Insights Engine**	As a patient, I want to see a timeline that shows	**Should Have**	R:9 I:9 C:8 E:3 = **21.6**	**Performance**	Data visualization library, backend data aggreg	47

		my nighttime symptoms, my daily feelings, and environmental data together, so I can spot patterns.				ation and analysis service.	
F05	**Exacerbation Risk Forecast**	As a patient, I want the app to warn me if my risk of a flare-up is increasing, so I can take proactive steps with my doctor.	**Should Have**	R:8 I:10 C:7 E:5 = **11.2**	**Delighter**	Cloud-based ML model (XGBoost/LSTM), data pipeline for model training/inference.	[42]
F06	**Smart Inhaler Integra**	As a patient with a	**Could Have**	R:2 I:6 C:9 E:4 = **2.7**	**Performance**	Bluetooth API integrat	[3]

	tion	smart inhaler, I want to sync its data with the app, so all my information is in one place.				ion (e.g., Propeller), data mapping to internal model.	
F07	**Inhaler Technique Audio Analysis**	As a patient, I want the app to listen to me use my inhaler and give me feedback, so I know I'm doing it correctly.	**Could Have**	R:7 I:8 C:7 E:5 = **7.8**	**Delighter**	On-device AI/ML audio classifier for inhalation/actuation sounds.	[16]
F08	**EHR Integration (FHIR)**	As a patient, I want my app data to be automatically available to my	**Won't Have (Post-MVP)**	R:6 I:8 C:6 E:8 = **3.6**	**Performance**	SMART on FHIR integration, API partnerships with EHR vendors (e.g.,	[62]

		doctor in my medical record, so we can have more informed conversations.				CommonHealth).	

Differentiated MVP Recommendation

The MVP will be rigorously focused on establishing a novel and valuable core user experience loop: **Sense -> Correlate -> Advise**. This approach is designed to deliver immediate value, minimize initial user friction, and strategically build the proprietary data asset necessary for future AI development.

1. **Sense (Passive & Active Data Capture):** The MVP's primary function will be data acquisition. It will passively collect nocturnal acoustic data using the on-device AI model (**F01**) and actively prompt the user for a simple, once-daily check-in to log subjective symptoms and rescue medication use (**F02**). In the background, it will continuously pull in localized environmental data (**F03**).
2. **Correlate (Initial Insight Visualization):** Critically, the MVP will *not* launch with a complex, black-box predictive model. Instead, its core value proposition will be a simple yet powerful visualization dashboard—an early iteration of the Correlational Insights Engine (**F04**). This dashboard will present the user with a synchronized timeline showing their objective nocturnal symptom events (e.g., cough count per hour), their self-reported daily symptoms, and key environmental factors. For the first time, a patient will be able to clearly see the relationship between a high pollen count on Tuesday, a spike in their coughing at 3 AM on Wednesday, and their report of feeling short of breath on Wednesday morning.
3. **Advise (Actionable Education):** The advisory component of the MVP will be based on established clinical guidelines, such as those from GINA.[20] The app will provide context-sensitive educational content and prompts. For example, if a consistent pattern of nocturnal symptoms is detected over several nights, the app will surface information explaining why nighttime symptoms are a key indicator of poor asthma control and will prompt the user with a suggestion: "We've noticed an increase in your nighttime

coughing. This can be an important sign to discuss with your doctor. Consider sharing your report at your next visit."

This MVP is strategically differentiated from all existing competitors for several key reasons:

- **Delivers an Immediate "Wow" Factor:** The act of passively capturing and revealing "invisible" nocturnal symptoms is a powerful "Delighter" feature. It provides novel, personal, and actionable insight from the very first night of use, a stark contrast to the empty state and high initial effort required by manual logging apps.
- **Dramatically Lowers User Burden:** This model fundamentally flips the user engagement paradigm. Instead of demanding that the user constantly feed it data, the Co-Pilot's primary data collection method works silently in the background while the user sleeps. This directly attacks the primary reason for churn in the digital health app market: user fatigue.
- **Builds the Proprietary Dataset:** This approach is not just a product strategy; it is a data acquisition strategy. The MVP is designed to immediately begin collecting a unique, high-value, longitudinal, and labeled dataset that no competitor possesses: objective acoustic biomarkers linked to patient-reported outcomes and granular environmental data. This dataset is the essential fuel required to build, train, and validate the future predictive models (**F05**).
- **De-risks the Regulatory Pathway:** By launching initially as a wellness and monitoring tool—one that helps users and their doctors track and visualize health data—the MVP can enter the market under a less stringent regulatory classification. This allows for rapid iteration, user growth, and data collection while the more complex clinical validation and premarket submission for the future predictive features are pursued in parallel.

VI. Navigating the Path to Market: Regulatory, Data, and Metric Strategy

A successful launch requires a sophisticated strategy that addresses the complex regulatory landscape for AI-enabled medical devices, a robust plan for data acquisition and governance, and a clear framework for measuring both technical and clinical success.

1. Regulatory Pathway: A Phased Approach for SaMD

The AI Co-Pilot will be developed and marketed as a Software as a Medical Device (SaMD). Its

regulatory journey will follow a deliberate, phased approach aligned with the evolving guidance from the U.S. Food and Drug Administration (FDA) on AI/ML-enabled devices.[53]

- **Phase 1 (MVP Launch - Wellness & Monitoring):** The initial MVP will be positioned with an intended use statement focused on helping users "track and understand their asthma and allergy symptoms to facilitate more informed conversations with their healthcare provider." By focusing on data collection, visualization, and guideline-based education, and explicitly avoiding diagnostic claims or treatment directives, the MVP will likely fall under a lower-risk classification. This may qualify for enforcement discretion or a Class I device designation, allowing for a faster path to market. During this phase, the development process will rigorously adhere to Good Machine Learning Practices (GMLP), ensuring robust software engineering, data security, and patient privacy from the outset.[54]
- **Phase 2 (Predictive Features - Class II Clearance):** The introduction of the Exacerbation Risk Forecast (**F05**) and other features that provide predictive, risk-stratifying information will elevate the device's risk profile, almost certainly requiring a Class II designation. This will necessitate a formal premarket submission, likely a 510(k), to the FDA.

The premarket submission for the predictive features will require comprehensive documentation addressing several key areas mandated by FDA guidance [53]:

- **Transparency & Bias Mitigation:** A cornerstone of the submission will be a thorough demonstration of how algorithmic bias was addressed. This involves providing detailed documentation of the datasets used for training and testing the AI models, including demographic breakdowns (age, sex, race, ethnicity) to prove the data is representative of the intended use population.[53] The model's architecture and decision-making processes must be made transparent and explainable to a clinical audience, ensuring it is not an uninterpretable "black box."
- **Predetermined Change Control Plan (PCCP):** To accommodate the adaptive nature of AI, a PCCP will be developed and submitted as part of the 510(k). This plan will prospectively define the specific types of modifications the AI model can undergo post-market (e.g., retraining on new user data within specified performance boundaries) without requiring a new FDA submission for each update.[54] Proactively establishing a PCCP is strongly encouraged by the FDA and is critical for maintaining a competitive, continuously improving product in the market.

2. Data & Metrics Plan: Fueling the AI Engine and Proving Value

The Co-Pilot's success is contingent on a dual-pronged data and metrics strategy: one to ensure the technical performance of the AI models and another to measure the product's

real-world impact on clinical outcomes and user engagement.

- **Data Acquisition Strategy:**
  - **Initial Model Prototyping:** The initial development and prototyping of the acoustic and predictive models will leverage publicly available datasets to establish baseline performance and refine model architecture. This includes sourcing acoustic data from repositories like the Gene Expression Omnibus (GEO) [69], clinical data from platforms like Kaggle [70], and population-level health characteristics from large-scale surveys such as the National Health and Nutrition Examination Survey (NHANES) and the Behavioral Risk Factor Surveillance System (BRFSS).[71]
  - **Proprietary Data Collection (Post-MVP Launch):** The core long-term strategy is the creation of a unique, proprietary dataset collected via the live application. This will be a rich, longitudinal dataset containing time-stamped acoustic biomarkers, patient-reported outcomes (ePROs), medication logs, granular environmental data, and, in future versions, data from integrated third-party wearables and sensors.
- **Key Performance Indicators (KPIs):** Success will be measured against a balanced scorecard of technical, product, and clinical metrics.
  - **AI Model Performance Metrics:**
    - *Acoustic Classifier (F01):* The performance of the cough and wheeze detection model will be rigorously evaluated using standard classification metrics, including **Accuracy**, **Precision**, **Recall**, **F1 Score**, and **Area Under the Receiver Operating Characteristic Curve (AUC)**.[6]
    - *Exacerbation Predictor (F05):* The predictive model's performance will be measured by its **AUC**, its **Sensitivity** (its ability to correctly identify patients who will have an exacerbation, minimizing false negatives), and its **Calibration** (how accurately its predicted risk probabilities match the actual observed frequency of exacerbations).[42]
  - **Product & Clinical Success Metrics:**
    - *Engagement & Retention:* Key product metrics will include **Daily and Monthly Active Users (DAU/MAU)**, **long-term retention rates** (e.g., Day 30, Day 90), and the completion rate of the daily check-in feature. These metrics are critical for assessing whether the product has overcome the user fatigue common to the category.
    - *Clinical Outcomes:* The ultimate measure of value will be demonstrated through clinical trials. Key endpoints will include a statistically significant **reduction in rescue inhaler use**, an **improvement in validated Asthma Control Test (ACT) scores**, a **reduction in ED visits and hospitalizations**, and improvements in patient-reported quality of life measures.[7]

The strategic design of the MVP—focused on providing immediate value through passive data collection—is intended to initiate a powerful data flywheel that becomes the company's primary competitive moat. As more users are attracted to the novel insights provided by the app, the proprietary dataset grows larger and more diverse. This richer dataset, in turn, allows

for the training of more accurate, more personalized, and more powerful predictive models. These superior models deliver even greater value to users, further accelerating user acquisition and data collection. This virtuous cycle creates a compounding competitive advantage. A competitor entering the market later will be fundamentally unable to replicate the Co-Pilot's predictive accuracy without first undertaking the multi-year process of building a comparable proprietary dataset from scratch. This data asset, and the superior AI it enables, becomes the central, defensible core of the business.

VII. Conclusion: The Strategic Imperative for a Proactive Respiratory Co-Pilot

The analysis presented in this report reveals a clear and urgent opportunity to redefine the standard of care in digital respiratory health. The current market is characterized by a fundamental disconnect between patient needs and available solutions, offering tools that are reactive, burdensome, and ultimately fail to address the core patient desire for control over their unpredictable condition. The commercial failure of hardware-centric models and the low engagement of manual-entry apps have created a strategic vacuum waiting to be filled by a superior, technology-driven approach.

A powerful inflection point has been reached, where advances in AI, the ubiquity of smartphone sensors, and the availability of real-time environmental data make a new paradigm possible. The AI-Driven Asthma & Allergy Co-Pilot is designed to seize this opportunity. It is not merely another digital diary or adherence tracker; it is conceived as an intelligent, proactive partner in a patient's health journey. Its value proposition is uniquely compelling because it directly addresses the most critical, unmet patient jobs: it passively senses objective symptoms that were previously invisible, it predicts future risk to prevent emergencies, and it provides personalized, actionable advice to help users avoid their specific triggers.

The recommended strategic path, beginning with a focused MVP, is designed for both immediate market impact and long-term defensibility. The MVP's ability to deliver a novel "wow" factor—revealing a user's own objective, nocturnal symptom data—will drive initial adoption and engagement by providing value from day one. This initial user base is the key to initiating the data flywheel, a virtuous cycle that leverages user engagement to build a proprietary data asset of unparalleled scale and richness. This asset will fuel the development of increasingly sophisticated predictive models, creating a compounding competitive advantage that will be exceptionally difficult for competitors to overcome.

By navigating a phased regulatory strategy, grounding the product in robust clinical evidence,

and relentlessly focusing on the patient's need for control and peace of mind, the AI Co-Pilot is positioned to move beyond the failed models of the past. It has the potential to become the indispensable, category-defining standard of care in digital respiratory health management, improving patient outcomes and capturing a significant share of a market in need of true innovation.

Works cited

1. Asthma Tracker on the App Store, accessed September 25, 2025, https://apps.apple.com/us/app/asthma-tracker/id930849539
2. The Best Mobile Apps to Recommend to Your Asthma Patients - Woodruff Medical, accessed September 25, 2025, https://woodruffmedical.edu/the-best-mobile-apps-to-recommend-to-your-asthma-patients/
3. Propeller® - Digital Therapeutics Alliance, accessed September 25, 2025, https://dtxalliance.org/products/propeller/
4. FDA Approves Teva's ProAir Digihaler for Asthma, COPD | RT - Respiratory Therapy, accessed September 25, 2025, https://respiratory-therapy.com/products-treatment/monitoring-treatment/therapy-devices/fda-approves-teva-proair-digihaler/
5. ArmonAir Digihaler (fluticasone propionate) FDA Approval History - Drugs.com, accessed September 25, 2025, https://www.drugs.com/history/armonair-digihaler.html
6. Automated Lightweight Model for Asthma Detection Using Respiratory and Cough Sound Signals - PMC - PubMed Central, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12071825/
7. Digital Asthma Program Improves Symptom Control Across Most Subgroups | AJMC, accessed September 25, 2025, https://www.ajmc.com/view/digital-asthma-program-improves-symptom-control-across-most-subgroups
8. Digital markers of asthma exacerbations: a systematic review - ERS Publications, accessed September 25, 2025, https://publications.ersnet.org/content/erjor/10/6/00014-2024
9. Asthma - Symptoms and causes - Mayo Clinic, accessed September 25, 2025, https://www.mayoclinic.org/diseases-conditions/asthma/symptoms-causes/syc-20369653
10. Asthma: Types, Causes, Symptoms, Diagnosis & Treatment - Cleveland Clinic, accessed September 25, 2025, https://my.clevelandclinic.org/health/diseases/6424-asthma
11. Asthma Symptoms and Triggers | Allergy & Asthma Network, accessed September 25, 2025, https://allergyasthmanetwork.org/what-is-asthma/asthma-symptoms-triggers/
12. Asthma - causes, symptoms and complications - Healthdirect, accessed September 25, 2025, https://www.healthdirect.gov.au/asthma
13. My Asthma Diary - Lung Health Foundation, accessed September 25, 2025,

https://toolkit.lunghealth.ca/lhftools/my-asthma-diary/
14. Know Your Asthma Triggers - MN Dept. of Health, accessed September 25, 2025, https://www.health.state.mn.us/diseases/asthma/managing/triggers.html
15. ASTHMA TRIGGERS, accessed September 25, 2025, https://asthma.org.au/wp-content/uploads/2021/01/AA2022_Asthma-Triggers_A4_v8_web.pdf
16. The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease, accessed September 25, 2025, https://figshare.le.ac.uk/articles/journal_contribution/The_evolving_landscape_of_digital_inhaler_platforms_and_adherence_support_in_chronic_airways_disease/29843786/1/files/57688498.pdf
17. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers, accessed September 25, 2025, https://jtd.amegroups.org/article/view/50478/html
18. A Smartphone App to Support Adherence to Inhaled Corticosteroids in Young Adults With Asthma: Multi-Methods Feasibility Study - JMIR Formative Research, accessed September 25, 2025, https://formative.jmir.org/2021/9/e28784
19. (PDF) A Smartphone App to Support Adherence to Inhaled Corticosteroids in Young Adults With Asthma: Multi-Methods Feasibility Study - ResearchGate, accessed September 25, 2025, https://www.researchgate.net/publication/354296477_A_Smartphone_App_to_Support_Adherence_to_Inhaled_Corticosteroids_in_Young_Adults_With_Asthma_Multi-Methods_Feasibility_Study
20. GINA Pocket Guide 2023 - Global Initiative for Asthma, accessed September 25, 2025, https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Pocket-Guide-WMS.pdf
21. Pediatric Asthma Management App Prototype (We need your input & opinions!) : r/UXDesign, accessed September 25, 2025, https://www.reddit.com/r/UXDesign/comments/ldgjze/pediatric_asthma_management_app_prototype_we_need/
22. Acoustic biomarkers in asthma: a systematic review - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/38634718/
23. The evolving landscape of digital inhaler platforms and adherence ..., accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12334831/
24. Teva wins FDA approval for AirDuo Digihaler for asthma - Guided Solutions, accessed September 25, 2025, https://www.gsmedtech.com/GS/NewsDetails/Teva-wins-FDA-approval-for-AirDuo-Digihaler-for-asthma
25. Propeller Health: Using Data to Help Patients Manage Their Respiratory Health - Digital Innovation and Transformation, accessed September 25, 2025, https://d3.harvard.edu/platform-digit/submission/propeller-health-using-data-to-help-patients-manage-their-respiratory-health/
26. AsthmaMD app | Healthify, accessed September 25, 2025,

https://healthify.nz/apps/a/asthmamd-app
27. Asthma overview - myDr.com.au, accessed September 25, 2025, https://mydr.com.au/asthma/asthma-overview/
28. myAsthma: The asthma app for managing your symptoms - MyMHealth, accessed September 25, 2025, https://mymhealth.com/myasthma
29. A Smartphone App to Support Adherence to Inhaled Corticosteroids in Young Adults With Asthma: Multi-Methods Feasibility Study - PMC, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8444040/
30. Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial - PMC, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11091812/
31. Best app for tracking asthma/peak flow - HealthUnlocked, accessed September 25, 2025, https://healthunlocked.com/asthmalunguk-asthma/posts/137330019/best-app-for-tracking-asthma-peak-flow
32. A Systematic Evaluation of Asthma Management Apps Examining Behavior Change Techniques - PMC, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6776707/
33. Discover Your Allergy Forecast | ZYRTEC®, accessed September 25, 2025, https://www.zyrtec.com/allergy-forecast
34. Allergy Plus App - Pollen.com, accessed September 25, 2025, https://www.pollen.com/tools/app
35. Allergy Plus by Pollen.com 4+ - App Store, accessed September 25, 2025, https://apps.apple.com/us/app/allergy-plus-by-pollen-com/id1556701665
36. Johnson & Johnson: ZYRTEC AllergyCast App with Symptom Tracker - MMA Global, accessed September 25, 2025, https://www.mmaglobal.com/case-study-hub/case_studies/view/27469
37. ZYRTEC - MMA Global, accessed September 25, 2025, https://www.mmaglobal.com/case-study-hub/upload/pdfs/mma-2013-586.pdf
38. Audio-based digital biomarkers in diagnosing and managing respiratory diseases: a systematic review and bibliometric analysis - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40368428/
39. About - AsthmaMD, accessed September 25, 2025, https://www.asthmamd.org/about/
40. Use of a digital tool to support and optimise high-risk asthma patients, accessed September 25, 2025, https://transform.england.nhs.uk/key-tools-and-info/digital-playbooks/respiratory-digital-playbook/use-of-a-digital-tool-to-support-and-optimise-high-risk-asthma-patients/
41. ZYRTEC® ALLERGYCAST® App - Kenvue Health Professionals, accessed September 25, 2025, https://kenvuepro.com/en-us/patient-education/allergycast
42. Machine Learning Can Play a Role in Predicting Acute Asthma Exacerbation, Study Finds, accessed September 25, 2025, https://consultqd.clevelandclinic.org/machine-learning-can-play-a-role-in-predicting-acute-asthma-exacerbation-study-finds

43. Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol, accessed September 25, 2025, https://www.tevapharm.com/news-and-media/latest-news/teva-launches-two-digital-inhalers-in-the-u.s.-airduo-digihaler-fluticasone-propionate-and-salmeterol
44. Features | AsthmaMD, accessed September 25, 2025, https://www.asthmamd.org/features/
45. ZYRTEC® AllergyCast® – Apps on Google Play, accessed September 25, 2025, https://play.google.com/store/apps/details/ZYRTEC_AllergyCast?id=com.mcneil.zyrtec.allergycast.activity&hl=en_IN
46. ZYRTEC® ALLERGYCAST® on the App Store, accessed September 25, 2025, https://apps.apple.com/us/app/zyrtec-allergycast/id320298020
47. EAACI guidelines on environmental science in allergic diseases and ..., accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/36740916/
48. Phil and Teva Pharmaceuticals Launch New Program to Improve Access, accessed September 25, 2025, https://phil.us/phil-and-teva-pharmaceuticals-launch-new-program-to-improve-access-to-the/
49. Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System - Teva Pharmaceuticals USA, accessed September 25, 2025, https://www.tevausa.com/news-and-media/press-releases/tevas-digital-health-collaboration-with-rimidi-expands-to-include-respiratory-monitoring-program-integra/
50. AsthmaMD on the App Store, accessed September 25, 2025, https://apps.apple.com/us/app/asthmamd/id349343083
51. myAsthma App - Trumpington Street Medical Practice, accessed September 25, 2025, https://www.trumpingtonstreetmedicalpractice.co.uk/news/myasthma-app
52. FDA Approves AirDuo Digihaler for Asthma | RT - Respiratory Therapy, accessed September 25, 2025, https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/asthma/fda-approves-airduo-digihaler-asthma/
53. FDA Guidance on AI-Enabled Devices: Transparency, Bias, & Lifecycle Oversight | WCG, accessed September 25, 2025, https://www.wcgclinical.com/insights/fda-guidance-on-ai-enabled-devices-transparency-bias-lifecycle-oversight/
54. Understanding FDA Guidance on AI in Medical Devices and Predetermined Change Control Plans (PCCPs) - Ketryx, accessed September 25, 2025, https://www.ketryx.com/blog/understanding-fda-guidance-on-ai-in-medical-devices-and-predetermined-change-control-plans-pccps
55. Introduction of the 'MyAsthma' application to aid managing complex asthma patients in the outpatient setting | HEIW, accessed September 25, 2025, https://heiw.nhs.wales/files/informing-the-future-virtual-conference-poster-submissions/introduction-of-the-myasthma-application-to-aid-managing-complex-asthma-patients-in-the-outpatient-setting/
56. Audio-based digital biomarkers in diagnosing and managing respiratory diseases:

a systematic review and bibliometric analysis - ERS Publications, accessed September 25, 2025, https://publications.ersnet.org/content/errev/34/176/240246
57. Machine Learning–Based Asthma Attack Prediction Models From Routinely Collected Electronic Health Records: Systematic Scoping Review - JMIR AI, accessed September 25, 2025, https://ai.jmir.org/2023/1/e46717/
58. Machine Learning-based Asthma Exacerbation Prediction Model from Routinely Collected Primary Care Data, accessed September 25, 2025, https://usher.ed.ac.uk/sites/default/files/atoms/files/p30_machine_learning-based_asthma_exacerbation_prediction_model_from_routinely_collected_primary_care_data.pdf
59. Predicting paediatric asthma exacerbations with machine learning: a systematic review with meta-analysis - ERS Publications, accessed September 25, 2025, https://publications.ersnet.org/content/errev/33/174/240118
60. Best Allergy Tracker App 2025 - The Best Allergy App For You - Bearable App, accessed September 25, 2025, https://bearable.app/best-allergy-tracker-app-2025/
61. Implementation of digital home monitoring and management of respiratory disease - PMC, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10241431/
62. User Experience Design for Adoption of Asthma Clinical Decision Support Tools - PMC, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9556170/
63. Developers | CommonHealth, accessed September 25, 2025, https://www.commonhealth.org/developers
64. FDA Issues Comprehensive Draft Guidance for Developers of Artificial Intelligence-Enabled Medical Devices, accessed September 25, 2025, https://www.fda.gov/news-events/press-announcements/fda-issues-comprehensive-draft-guidance-developers-artificial-intelligence-enabled-medical-devices
65. Good Machine Learning Practice for Medical Device Development ..., accessed September 25, 2025, https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles
66. Artificial Intelligence-Enabled Device Software Functions ... - FDA, accessed September 25, 2025, https://www.fda.gov/media/184856/download
67. Asthma management in the digital age - PMC - PubMed Central, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11405314/
68. FDA AI Guidance - A New Era for Biotech, Diagnostics and Regulatory Compliance, accessed September 25, 2025, https://www.duanemorris.com/alerts/fda_ai_guidance_new_era_biotech_diagnostics_regulatory_compliance_0225.html
69. Machine learning-based screening of asthma biomarkers and related immune infiltration, accessed September 25, 2025, https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2025.1506608/full
70. An Interpretable and Generalizable Machine Learning Model for Predicting

Asthma Outcomes: Integrating AutoML and Explainable AI Techniques - MDPI, accessed September 25, 2025, https://www.mdpi.com/2673-4060/6/1/15
71. Asthma Data Sets from National Health and Nutritional... - R, accessed September 25, 2025, https://search.r-project.org/CRAN/refmans/AsthmaNHANES/html/AsthmaNHANES.html
72. Behavioral Risk Factor Surveillance System (BRFSS) Dashboard - Florida Health CHARTS, accessed September 25, 2025, https://www.flhealthcharts.gov/charts/LoadPage.aspx?l=rdPage.aspx?rdReport=BRFSS.Dataviewer&bid=0020
73. Predicting asthma attacks (exacerbations): performance of current instruments, accessed September 25, 2025, https://www.aaaai.org/tools-for-the-public/latest-research-summaries/the-journal-of-allergy-and-clinical-immunology-in/2018/asthma-attack